Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

In this study (n=387), more patients randomised to abrocitinib achieved an Investigator Global Assessment response (24% for 100mg [p=0.0037] and 44% for 200mg [p<0.0001] vs 8% placebo) and an EASI-75 response (40% for 100mg [p<0.0001] and 63% for 200mg [p<0.0001] vs 12% placebo).

SPS commentary:

Abrocitinib is an oral selective Janus kinase 1 inhibitor in development for the treatment of atopic dermatitis. A related commentary notes that it was well tolerated during the 12-week observation period, which is to be expected considering that most side-effects of JAK inhibitors result from chronic use. As JAK inhibition affects the haematopoietic system, the observed transient dose-related decreases in median platelet count require further investigation. Further study is required to determine longer-term efficacy and safety.


The Lancet

Resource links: